0400: Degenerative calcific mitral stenosis in patients referred for high surgical risk aortic stenosis: detection and quantification by multi-detector computed tomography  by Bouvier, Erik et al.
© Elsevier Masson SAS. All rights reserved.
 
52 Archives of Cardiovascular Diseases Supplements (2016) 8, 51-65
0150
Feasibility and safety of early discharge after transfemoral transcatheter
valve implantation with balloon-expandable prosthesis: a prospective
study
Guillaume Cellier*, Eric Durand, Christophe Tron, Safwane El Hatimi,
Alain Cribier, Helene Eltchaninoff 
CHU Rouen, Charles Nicolle, Rouen, France
*Corresponding author: cellier_guillaume1986@yahoo.fr (Guillaume Cellier)
Introduction There is currently no consensus on the duration of hospita-
lization required after transfemoral transcatheter valve implantation (TF-
TAVI). 
We recently reported, retrospectively, that early discharge (within 3 days)
was feasible in 31% and safe without any death and a low rate of re-hospital-
ization at 30 days. We therefore aimed to confirm the feasibility and safety of
early discharge after TF-TAVI in a prospective study.
Methods After implementation of an early discharge pathway in our center
in January 2014, we included prospectively, between January 2014 and Jan-
uary 2015, 130 consecutive patients scheduled for TF-TAVI with Edwards
prosthesis using exclusively local anesthesia. The primary end-point combined
death and re-hospitalization from discharge to 30-day follow-up. The propor-
tion of early discharge (within 3 days) and the cause of "non-early" discharge
were also assessed.
Results During the studied period, the mean length of stay was 4.0±2.7
days and 76 (58.6%) patients were discharged early within 3 days including
55 (42.3%) patients discharged within 2 days after the procedure. The main
causes of non-early discharge were conduction abnormalities in 33 (25%)
patients, major vascular complications in 18 (13.8%) patients, social issues in
11 (8.5%) patients, heart failure in 3 (2.3%) patients, and acute kidney injury
in 2 (1.5%) patients. Finally, between discharge and 30-day follow-up, there
was no death and only 5 (6.5%) patients required re-hospitalization.
Conclusions Early discharge is feasible in slightly over 50% of cases in
selected patients scheduled for TF-TAVI using a balloon-expandable and local
anesthesia, and is associated with no death and a very low rate of readmission
at 30 days. The two main causes of non-early discharge are occurrence of new
conduction disturbances and major vascular complications.
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Mitral valve prolapse (MVP) by Barlow disease is recognized a genetic
disease. Fibro-elastic deficiency (FED)-MVP is considered a pure degenera-
tive condition. FLNA, the first gene involved in MVP, encodes for Filamin-A,
a cytoskeleton associated protein. It interacts with a protein named Filgap,
encoded by ARHGAP24 (Chr. 4), in the mechanical transduction. We hypoth-
esized that ARHGAP24 mutations could elicit MVP with same pathway.
Four probands with ARHGAP24 mutations were identified among
96 MVP. By a familial echocardiographic screening we enrolled 19 adults of
whom 13 had an ARHGAP24 mutation. The mutated group was matched with
a control group of 39 healthy adults. Anterior (AML) and posterior (PML)
mitral leaflets length and thickness were measured. The coaptation point posi-
tion was the ratio of coaptation height on the systolic annulus diameter. MVP
(displacement >2mm above the annulus line), minimal systolic displacement
(MSD, displacement <2mm) and abnormal antero-posterior coaptation posi-
tion (AAC, ratio <60%) were assessed. 
The conjunction of MSD and AAC defines a MVP prodromal form (MVP-
prod).
There was no difference between the two groups on baseline characteris-
tics. Leaflets were thin in the mutated group (PML: 2.7±1 vs 2.2±0.5mm in
control, P=0.21, AML: 2.5±0.9 vs 2.1±0.4mm, P=0.25), as reported in FED-
MVP. Only the PML was elongated (8.2±1.6 vs 6.0±1.2mm/m2, P=0.0003) in
the mutated group, leading to an anterior displacement of the coaptation point
(51±11 vs 66±7%, P=0.0003). Abnormal mitral phenotype (70% of MVP,
23% of MVP prod) and mitral regurgitation (93 vs 38%, P=0.0007) were fre-
quent in the mutated group. Two probands were operated for severe MR
related to chordal rupture; histological examination confirmed the leaflets
thinness.
ARHGAP24 is the first gene for autosomal dominant inherited MVP. Our
limited series of patients exhibit typical features of FED-MVP. Our results
could change the paradigm of a pure degenerative disease for FED-MVP.
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Studies that investigate the secretion of BNP in diseases affecting the
atrium are rare. The relationship between N-terminal proBNP (NT-proBNP)
and the echocardiographic (TTE) and hemodynamic data were studied in cases
of pure and isolated rheumatic mitral stenosis (RMS). 67 patients with MS
(41±11 years), and 29 healthy individuals (age 36±11 years) were included in
the study. Detailed TTE was performed before, one and six months after PMC
.we measured NT pro BNP in systemic venous and left atrial (LA) before,
immediately after, and one and 30 days after the procedure. 
Results The plasma levels of NT-proBNP were significantly higher in MS
patients than in controls (103.2±116.8 VS 21.5±8.5pg/mL, p=0.004).We
revealed a strong correlation between levels of NT pro-BNP in peripheral vein
(PV) and in LA (r=0.819, p=0.001). NT-proBNP was higher in the LA than
PV. We releaved a positive correlation with LA volume (0.470, p=0.001 and
p=0.001, 0.681 respectively at the LA and at the PV), the absolute value of
LV strain (r=0.524, p=0.001 and r=0.568, p=0.001) and the pulmonary artery
pression (PAP) (r =0.312, p=0.01 and r=0.586 p=0.001). Negative correlations
with LVEF (r=–0.421, p=0.001 and r=-0,462, p=0.000) and the longitudinal
movement of the VD (r=-0,380, p=0.002 and r=–0,374, p=0.001) were
observed. NT pro BNP falls immediately after PMC IN the sinus rythm (SR)
group patients but not in the atrial fibrillation (AF) group. Moreover, LA
remodeling at six months is more pronounced in SR (SOG=0.04±0.07 VS
0.02±0.06 in the AF group; LA volume=5.94±6.5 VS 1.17±8.6
Conclusion In patients with RMS, NT-proBNP was positively correlated
with LA enlargement and the PAP and could be a valuable marker to reflect
the structural changes of the LA aftercmP, in patients with SR but not in those
with AF.
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Background Mitral annular calcifications (MAC) is a common finding in
elder patients referred for transcatheter aortic valve implantation (TAVI),
sometimes responsible of significant degenerative calcified mitral stenosis
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(CaMS), but prevalence of both is poorly defined. Multidectector computed
tomography (MDCT) allows fine quantification of calcifications and is a reli-
able tool in rheumatic mitral stenosis, but its contribution in CaMS remains
unknown. Our objective was to estimate prevalence of MAC and CaMS in
patients referred for TAVI using MDCT, and determine morphological factors
leading from MAC to CaMS.
Methods and results A cohort of 346 consecutive patients referred for
TAVI evaluation was screened by MDCT for MAC. One hundred and sev-
enty four patients were positive for MAC. Among these patients, 165
patients had mitral valve area (MVA) assessable by MDCT planimetry
(mean age 84 years). Analysis by segment revealed calcifications on: A1
30.9%, A2 29.1%, A3 42.4%, P1 56.4%, P2 78.8%, P3 69.7%. Mean
mitral calcification volume and MVA were 1020±1398mm3 and
246±90mm2, respectively. CaMS were severe, moderate and mild in 2.4%,
21.8% and 9.7% patients, respectively. Correlation between mitral calcifi-
cation volume and MVA was significant but moderate (r=–0.433). On mul-
tivariate analysis, MVA was independently linked to mitral calcification
volume, aortic annular area and specific patterns of mitral leaflet calcifi-
cation underlining the role of A2 (AUC 0.81). Interobserver reproduc-
ibility of MVA was high (ICC 0.935).
Conclusions MDCT allows detailed assessment of MAC in TAVI pop-
ulations, demonstrating high prevalence, and quantification of CaMS with
high reproducibility. Mitral analysis should become routine during MDCT
screening before TAVI as it may significantly alter the therapeutic
strategy.
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Introduction Percutaneous mitral commissurotomy (PMC) is the alterna-
tive treatment of choice for mitral stenosis (MS). Its immediate and medium
term results are comparable to those of surgical commissurotomy, however in
the long term there is a risk of restenosis. The purpose of this study is to deter-
mine the factors predicting restenosis after PMC.
Methods 322 patients (66% women), average age: 35±13 years (9-75
years) having a tight MS and treated by PMC with Inoué balloon. The ana-
tomic aspect of the mitral apparatus before PMC was studied according to the
criteria of the Wilkins score with a concomitant study of the state of mitral
commissures. The primary success of PMC was defined as follow: mitral area
(MA) post-PMC >1,5cm2 and gain in MA >25% and mitral regurgitation
(MR) ≤grade 2. Mitral restenosis was defined as a MA <1,5cm2 and/or loss
>50% of initial gain in MA.
Results The rate of primary success of PMC was 86% and mean MA post
PMC was 1,82±0,33cm2 compared to MA pre-PMC of 1±0,18cm2 (p<0.0001).
Opening of two commissures was observed in 74% of patients. After an
average period of 62±32 months, only 12% of patients had a dyspnea stage
III-IV of NYHA, MA was 1,64±0.3cm2 (p<0.001) and mitral restenosis
happened in 47 patients (20%) after a period of 60,48±27 months (22 –
124 months).
The independent predictors of mitral restenosis after a successful PMC
were: previous surgical commisurotomy, Wilkins score >8, MA after PMC
<1,8cm2 and absence of bicommissural opening post PMC.
Conclusion A favorable anatomy of mitral apparatus and the optimisation
of immediate result of PMC are the guaranty for the maintain of good result
in the long term.
The author hereby declares no conflict of interest
0263
Short- and long-term outcomes of surgery for severe tricuspid regur-
gitation: Algerian experience
Hocine Foudad*, Ilyas Bouaguel, Aziz Trichine, Rachid Merghit, Tayeb
Adjabi 
Hôpital Militaire, Constantine, Algérie
*Corresponding author: hfoudad@yahoo.com (Hocine Foudad)
Introduction and objectives There is little data available for Algeria on the
outcomes of surgical treatment for severe tricuspid regurgitation. The aim of this
study was to analyze clinical and echocardiographic outcomes in a series of patients
who received surgical treatment for severe tricuspid regurgitation and to compare
outcomes according to the operative approach to valve repair or replacement. 
Methods Retrospective study in 239 consecutive patients with severe tri-
cuspid regurgitation undergoing valve surgery between April 2006 and
February 2014 in military hospitals of Algeria and Constantine. 
Results A total of 112 ringless and 85 ring annuloplasties were performed and
9 bioprostheses and 33 mechanical prostheses were implanted. Perioperative mor-
tality was 18.5% and was associated with age and cardiopulmonary bypass time.
During clinical follow-up (median, 41 [interquartile range, 24-89] months), 2 reop-
erations were required in the ring annuloplasty and mechanical prosthesis groups;
prosthetic thrombosis was diagnosed in 4 patients in the latter group. Total mor-
tality after follow-up was 29.9% and was associated with age>70 years and extra-
corporeal circulation time. The emergence of new severe tricuspid regurgitation
was associated with age and ringless annuloplasty (P=.04). 
Conclusions Ringless repair was significantly associated with recurrence
of severe tricuspid regurgitation. The use of mechanical prostheses was asso-
ciated with a high rate of thrombosis. No significant differences in periopera-
tive or total mortality were found between the different methods used for
repair or valve replacement.
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Objectives The importance of the left atrial appendage (LAA) on left atrial
(LA) hemodynamics is unknown. We sought to evaluate the effect of LAA
percutaneous closure (LAAPC) on left atrial remodeling in patients with par-
axysmal atrial fibrillation (AF) and permanent AF.
Methods All patients refered for LAAPC with Amplatzer Cardiac Plug
(ACP) and Watchman device were enrolled. Cardiac computed tomography
(CT) for LA volume measurement and transthoracic echocardiography (TTE)
for diastolic function assessment were performed at baseline and 3 months
after LAAPC. An average of 3 consecutives measurements were performed
for TEE parameters in all patients.
Results Sixty-three patients (mean age 73±9 years) were included. 38%
(n=24) in sinus rythm (SR) at baseline and 55% (n=35) in permanent AF.
Patients in SR at baseline and permanent AF at 3 months were excluded
(n=4,7%).The mean CHA2DS2-VASc score was 4,3±1,3. There was non sig-
nificant difference in the functionnal status and BNP level (155,6±107 vs
±150,7pg/mL; p=0,85) between baseline and 3 months follow-up. Left atrial
volume excluding the LAA (145 ±55cm3 baseline vs 144±50cm3 at 3 months;
p=0,30) showed no significant change after 3 months in overall population,
neither in the SR (99,7±19,1 vs 103,8±21cm3; p=0,32) or the permanent AF
groups (173,2±54 vs 171,7±48,6cm3; p=0,59). MV peak E-wave (84,2±22,7
vs 86,7±26cm/s; p=0,62) and A-wave velocities (65,4±14,4; 68,5±22,2cm/s;
p=0,66) dit not differ between baseline and follow-up but E/E’ ratio was
increased in the overall population after LAAPC (7,9±2,1 vs 9,1±3,6cm/s;
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